Combined radiofrequency ablation and high–dose rate brachytherapy for early-stage non–small-cell lung cancer
To access this article, please choose from the options below
Financial disclosures: Dr. Dupuy receives grant support from the following sources: Angiodynamics, Veran Medical, Biotex, BSD Medical, and Medwaves. Dr. Dupuy also serves as a speaker and consultant for Convidien and as a consultant for Ethicon Endosurgery.
PII: S1538-4721(10)00297-7
doi:10.1016/j.brachy.2010.07.002
© 2011 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
